Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -49.04% is 32% above its 5-year average of -71.96%, near the high end of its 5-year range (-131.20%–-18.96%).
34.68% above its 12-month average of -75.08%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -20.28%.
RETURN ON ASSETS (ROA)
-49.04%
RETURN ON ASSETS (ROA) AVG TTM
-75.08%
RETURN ON ASSETS (ROA) AVG 3Y
-74.95%
RETURN ON ASSETS (ROA) AVG 5Y
-71.96%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+34.68%
CURRENT VS 3Y AVG
+34.57%
CURRENT VS 5Y AVG
+31.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.94%
median of 765 covered companies
CURRENT VS SECTOR MEDIAN
-58.50%
vs the sector median at left
Invivyd, Inc.
Market Cap
$241.02M
Return on Assets (ROA)
-49.04%
TTM Avg
-75.08%
3Y Avg
-74.95%
5Y Avg
-71.96%
Market Cap
$241.80M
Return on Assets (ROA)
-34.55%
TTM Avg
-30.02%
3Y Avg
-24.36%
5Y Avg
-21.40%
Market Cap
$242.35M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$242.54M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$242.57M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$239.07M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$243.06M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$238.91M
Return on Assets (ROA)
-8.99%
TTM Avg
-7.90%
3Y Avg
-14.69%
5Y Avg
-13.78%
Market Cap
$238.48M
Return on Assets (ROA)
-1.57%
TTM Avg
17.43%
3Y Avg
19.75%
5Y Avg
24.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $241.02M | -49.04% | -75.08% | -74.95% | -71.96% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $241.80M | -34.55% | -30.02% | -24.36% | -21.40% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | -187.80% | -213.40% | -188.65% | -151.14% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.54M | -114.79% | -67.19% | -63.94% | -45.91% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.57M | -244.25% | -369.36% | -230.97% | -157.86% |
| InflaRx N.V. (IFRX)vs › | $239.07M | -23.88% | -71.64% | -51.89% | -47.09% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.06M | N/A | -14.72% | -16.00% | -18.82% |
| High Tide Inc. (HITI)vs › | $238.91M | -8.99% | -7.90% | -14.69% | -13.78% |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | -1.57% | 17.43% | 19.75% | 24.82% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $238.29M | -8.48% | -16.43% | -20.20% | -32.31% |
ROA
-49.0%
ROE
-59.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -18.96% |
| 2024-12-31 | -131.20% |
| 2023-12-31 | -86.68% |
| 2022-12-31 | -62.98% |
| 2021-12-31 | -36.57% |
| 2020-12-31 | -95.39% |
